NCT00463983

Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide

Phase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary Fibrosis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Institut National de la Santé Et de la Recherche Médicale, France · Other Government
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Octreotide is a somatostatin analog with a long half-life in vivo. Octreotide has interesting anti-inflammatory and anti-fibrotic properties in vitro and in vivo. Somatostatin receptors are increased and Octreotide uptake is increased in the lung in patients with idiopathic pulmonary fibrosis. Our hypothesis is that octreotide may slow the degradation of lung function in patients with IPF. In this proof of concept study, patients with IPF will receive an intramuscular injection of slow release octreotide (Sandostatin LP, 30 mg)every 4 weeks for 48 weeks. Lung function (FVC, DLCO), HRCT scores for fibrosis and ground glass, 6 minute walking test,quality of life and survival will be monitored.

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	octreotide

Timeline

• Start date: 2006-10-01
• Primary completion: 2010-01-01
• Completion: 2012-01-01
• First posted: 2007-04-20
• Last updated: 2025-03-05

Locations

16 sites across 1 country: France